HER2
Interviews and expert commentary tagged “HER2” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.
AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c
19 November 2013
0:00
Audio Journal of Oncology
ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007
Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract: 2090 RACHEL JOHNSON, Christie Hospital, Manchester Som
16 February 2007
0:00
Audio Journal of Oncology
Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer
IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in th
17 January 2007
0:00